MedPath

Evaluation of the efficacy of oral N- acetylcysteine in the treatment of vitiligo patients

Phase 3
Recruiting
Conditions
vitiligo disease.
Vitiligo
Registration Number
IRCT20210729052013N1
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

People with generalized vitiligo who volunteer for NB-UVB phototherapy

Exclusion Criteria

Patients with focal or segmental vitiligo
Patients with other skin diseases
Patients with a history of gastrointestinal ulcers
Patients with photosensitivity
Patients who have received systemic or topical medication for 2 months
Pregnant and lactating women

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Vitiligo severity score. Timepoint: At the beginning of the study (before the intervention), 2 and 4 months after the start of treatment. Method of measurement: Vitiligo Extent Tensity Index (VETI) score, which its maximum value is 55.5.
Secondary Outcome Measures
NameTimeMethod
The patient's tolerance of the treatment. Timepoint: Measurement periods: 2 and 4 months after starting treatment. Method of measurement: At each visit, patients determine their tolerance by choosing one of the following options: 1. Yes 2. No.;The patient's satisfaction with the treatment. Timepoint: Measurement periods: 2 and 4 months after starting treatment. Method of measurement: At each visit, patients determine their level of satisfaction by choosing one of the following options: 1. No 2. A little 3. Moderate 4. Good 5. Excellent.
© Copyright 2025. All Rights Reserved by MedPath